STOCK ANALYSTS

                 AU SMALL FINANCE BANK   Q4&FY21 BUSINESS UPDATES   Key Q4FY21 Highlight -  Q4FY21 Quarterly Result -  Key FY21 Financial Highlights -  FY21 Annual Result -  Other Income Statement -  Balance Sheet -  Assets & Liabilities Breakup -  Key FY21 Operational Highlights -  ➢ Strong rebound in disbursement in H2 (Vehicle, SBL and Housing)  ➢ 77% of total FY21 disbursement in H2 (47% YoY growth) ➢ Deposits continue to scale driven by increasing brand awareness, branch expansion and improved digital offering ➢ Improved CASA ratio from 14% to 23% ➢ Overall Cost of Funds reduced by 86 bps to 6.83% from 7.69% in FY20 ➢ GNPA of ₹ 1,503 Cr (4.3%), of which ➢ >90DPD portfolio - ₹ 962 Cr (2.7%)  ➢ <90 DPD portfolio - ₹ 541 Cr (1.5%) ➢ Collection efficiency was >100% in each month of Q4FY21 ➢ PAT (ex-Aavas) grew YoY despite accelerated provisions in FY21 ➢ Deposit are at 35,979 crore ( Growth of 38%)(y-o-y) Share Holdings Pattern - 

       I OLCP Q4&FY21 Business Updates   Company Overview -  • Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities • Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share • Largest producer of Ethyl Acetate at Single Location in India • 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share • Over 20 products are commercialised with 8 products in pipeline • Debt free company, No debt raised since 2017 • Customer base across 80 countries. Key Financial Summary -  P&L Statement -  Balance sheet  -  Pharmaceuticals Product wise Segmentation -  Chemicals Product wise Segmentation -  Key Financial Numbers -  1. Imports (in crore) - 613 crore 2. Export (in crore) - 1354 crore 3. Debt/equity  - 0 4. Pharma EBITDA Margin - 39% 5. Chemical EBITDA Margin - 12% * Dr. Sanjay Chaturvedi is appoin

                Alkem laboratories ltd Q4&FY21 Business Updates Overview  - Alkem laboratories is established in 1973. Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India that manufactures and sells pharmaceutical generics, formulations and nutraceuticals in India and globally . Q4-FY21 Financial Highlights -  * Revenue from Operations -  * Revenue from India -  * Revenue from Outside -  * EBITDA And EBITDA Margins -  * Profit After Tax -    FY21:Key Financial Highlights   Indian Business -  • India sales contributed 68.1% to total sales in Q4FY21 • Company witnessed good recovery in the second half of the financial year compared to YoY decline in the first half • Company’s Trade Generic business delivered a robust growth during the quarter and the financial year • In Q4FY21, the Company’s secondary sales grew by 9.8% YoY compared to IPM growth of 8.5% YoY (Source: IQVIA data) • During the quarter, the Com

  Corporate Participants: George Alexander Muthoot  —  Managing Director Oommen K. Mammen  —  Chief Financial Officer K.R. Bijimon  —  Chief General Manager Analysts: Kunal Shah  —  Analyst Piran Engineer  —  Motilal Oswal — Analyst Digant Haria  —  GreenEdge Wealth Services — Analyst Anand Bhavnani  —  White Oak Capital — Analyst Subrat Dwibedy  —  SBI Life Insurance Co — Analyst Dhaval Gada  —  DSP Mutual Fund — Analyst Prashant Sridhar  —  SBI Mutual Fund — Analyst Manan Tijoriwala  —  ICICI Prudential Asset Management — Analyst Aswin Balasubramanian  —  HSBC Asset Management — Analyst Amit Ganatra  —  HDFC Mutual Fund — Analyst Alpesh Mehta  —  Motilal Oswal Financial Services Ltd — Analyst Vikas Kasturi  —  Focus Capital — Analyst Vikram Subramanian  —  Spark Capital Advisors — Analyst Sayantan Bhowmick  —  PineBridge Investments — Analyst Susmit Patodia  —  Motilal Oswal Asset Management — Analyst Dipanjan Ghosh  —  Kotak Securities — Analyst Sanket Chheda  —  Batlivala & Kar